bioMérieux S.A. (BMXMF)
| Market Cap | 11.20B -23.2% |
| Revenue (ttm) | 4.56B -3.2% |
| Net Income | 528.50M +22.4% |
| EPS | 4.38 +23.0% |
| Shares Out | n/a |
| PE Ratio | 21.71 |
| Forward PE | 19.91 |
| Dividend | 1.13 (1.19%) |
| Ex-Dividend Date | Jun 9, 2026 |
| Volume | 105 |
| Open | 95.00 |
| Previous Close | 102.14 |
| Day's Range | 95.00 - 95.00 |
| 52-Week Range | 77.00 - 132.05 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 26, 2027 |
About bioMérieux
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]
Financial Performance
In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.
Financial numbers in EUR Financial StatementsNews
bioMerieux downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded bioMerieux (BMXMF) to Hold from Buy with a EUR 95 price target
bioMerieux price target raised to EUR 84 from EUR 71.60 at JPMorgan
JPMorgan raised the firm’s price target on bioMerieux (BMXMF) to EUR 84 from EUR 71.60 and keeps a Neutral rating on the shares.
BioMerieux Records 9% Sales Growth In Q3 Amid New Test Launches; Reaffirms 2026 Guidance
(RTTNews) - bioMerieux S.A. (BIM.PA), a diagnostics company, on Monday reported financial results from the third quarter, noting a significant sales growth and confirmed earnings guidance for the full...
bioMérieux Earnings Call Transcript: Q3 2026
Q3 organic sales grew 8%, led by broad-based growth in GO•28 drivers, while a Cyclospora-related one-off lifted BIOFIRE non-respiratory growth. FY 2026 sales and CEBIT guidance was reaffirmed amid respiratory and input-cost uncertainty.
bioMérieux Earnings release: Q3 2026
bioMérieux released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Biomérieux third-quarter sales grew more than expected
Biomérieux French biotechnology firm Biomérieux reported on Tuesday a better-than-expected organic sales growth in the third quarter, helped by a 13% increase across key growth areas under its GO28 ...
bioMerieux upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Jan Koch upgraded bioMerieux (BMXMF) to Buy from Hold with a price target of EUR 103, up from EUR 75. The firm no longer sees downside risk…
Consensus Price Target for bioMérieux S.A. - Depositary Receipt Decreased by 24.45% to $9.77
The average one-year price target for bioMérieux S.A. - Depositary Receipt (OTCPK:BMXXY) has been revised to $9.77 / share. This is a decrease of 24.45% from the prior estimate of $12.93 dated June 8,...
bioMerieux price target raised to EUR 66 from EUR 64 at Morgan Stanley
Morgan Stanley raised the firm’s price target on bioMerieux (BMXMF) to EUR 66 from EUR 64 and keeps an Underweight rating on the shares.
bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual...
bioMerieux price target lowered to EUR 75 from EUR 78 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on bioMerieux (BMXMF) to EUR 75 from EUR 78 and keeps a Hold rating on the shares.
bioMérieux Earnings Call Transcript: H1 2026
Q2 2026 delivered a strong rebound with 5% organic sales growth, offsetting a weak Q1 and supporting full-year guidance of 3%-5% sales growth and 0%-10% EBIT growth. Free cash flow surged 76% year-over-year, and the midterm outlook was revised to 3%-6% annual sales growth amid ongoing cost and market pressures.
bioMérieux Earnings release: H1 2026
bioMérieux released its H1 2026 earnings on July 28, 2026, summarizing the period's financial results.
bioMérieux Slides: H1 2026
bioMérieux has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 28, 2026.
bioMérieux Quarterly report: H1 2026
bioMérieux has published its H1 2026 quarterly earnings report on July 28, 2026.
bioMerieux downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded bioMerieux (BMXMF) to Underweight from Equal Weight with a price target of EUR 64, down from EUR 100. The firm sees a slowdown in respiratory volumes impacting…
bioMerieux price target lowered to EUR 78 from EUR 81 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on bioMerieux (BMXMF) to EUR 78 from EUR 81 and keeps a Hold rating on the shares. Published first on…
bioMerieux initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of bioMerieux (BMXMF) with a Neutral rating and EUR 80 price target The firm launched coverage of the life science tools sector with a “feet in…
bioMerieux downgraded to Neutral from Buy at UBS
UBS downgraded bioMerieux (BMXMF) to Neutral from Buy with a price target of EUR 80, down from EUR 138. The company’s near-term visibility is less than previously assumed, the analyst…
bioMérieux Slides: FY 2026
bioMérieux has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 28, 2026.
bioMerieux price target lowered to EUR 71.60 from EUR 120.50 at JPMorgan
JPMorgan lowered the firm’s price target on bioMerieux (BMXMF) to EUR 71.60 from EUR 120.50 and keeps a Neutral rating on the shares.
bioMerieux downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Jan Koch downgraded bioMerieux (BMXMF) to Hold from Buy with a price target of EUR 81, down from EUR 120. The firm views the company’s profit warning…
bioMérieux Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3.9% sales decline due to weak respiratory demand and geopolitical headwinds, but core reagent growth remained strong. Guidance for 2026 was revised down to 3%-5% sales growth and 0%-10% EBIT improvement, with cost controls and innovation initiatives ongoing.
bioMérieux Earnings release: Q1 2026
bioMérieux released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
bioMerieux price target lowered to EUR 100 from EUR 108 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on bioMerieux (BMXMF) to EUR 100 from EUR 108 and keeps an Equal Weight rating on the shares.